Inicio / Oncología / Abstracts de oncología / A hotspot mutation in transcr…

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation

0 / 5 (0 votos)
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation

Cancer Cell

Fecha de publicación: 8 de marzo de 2021

DOI: https://doi.org/10.1016/j.ccell.2021.02.003

Autores: Gregory Lazarian , Shanye Yin , Elisa ten Hacken , Tomasz Sewastianik, Mohamed Uduman, Alba Font-Tello, Satyen H. Gohil, Shuqiang Li, Ekaterina Kim, Heather Joyal, Leah Billington, Elizabeth Witten, Mei Zheng, Teddy Huang, Mariano Severgnini, Valerie Lefebvre, Laura Z. Rassenti, Catherine Gutierrez, Katia Georgopoulos, Christopher J. Ott, Lili Wang, Thomas J. Kipps,Jan A. Burger, Kenneth J. Livak, Donna S. Neuberg, Fanny Baran-Marszak, Florence Cymbalista, Ruben D. Carrasco, Catherine J. Wu 

Background: Hotspot mutation of IKZF3 (IKZF3-L162R) has been identified as a putative driver of chronic lymphocytic leukemia (CLL), but its function remains unknown. Here, we demonstrate its driving role in CLL through a B cell-restricted conditional knockin mouse model. Mutant Ikzf3 alters DNA binding specificity and target selection, leading to hyperactivation of B cell receptor (BCR) signaling, overexpression of nuclear factor κB (NF-κB) target genes, and development of CLL-like disease in elderly mice with a penetrance of ~40%. Human CLL carrying either IKZF3 mutation or high IKZF3 expression was associated with overexpression of BCR/NF-κB pathway members and reduced sensitivity to BCR signaling inhibition by ibrutinib. Our results thus highlight IKZF3 oncogenic function in CLL via transcriptional dysregulation and demonstrate that this pro-survival function can be achieved by either somatic mutation or overexpression of this CLL driver. This emphasizes the need for combinatorial approaches to overcome IKZF3-mediated BCR inhibitor resistance.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.